Aberrant Malignancies

SuperVillain Cell

Explore signaling pathway data in highly active aberrant malignancies. Published in high-impact journals, such as Cancer Cell and Nature Communications, these datasets contain information on supervillain cells revealing insights into the functional mechanisms of resistance and disease progression.

Explore Protocols Across All Cell Types

Dropdown

Select Protocol

Mouse Bone Marrow (BM) CD117+ (cKIT) Cells Human Tumor Associated Endothelial Cell (EC) Human NK Cell Mouse Monocyte Human Tumor Associated Fibroblasts Human CD154+ T Cell Mouse T-Cells with PMA & Ionomycin Human CD34+ Myeloid Stem Cell HeLa Cell Human PBMC with PMA & Ionomycin Mouse T-cells Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8 Human PBMC Human Bispecific TCR-T Human Monocyte Using Membrane Stain

Explore by Cell Types, Applications & Biomarkers

Explore the Cell Library

Aberrant Malignancies by Cell Types, Applications & Biomarkers

Biomarkers at a Glance

Biomarker	Cell Type	Application	Publication	Journal & Year	Protocol
Immunosuppression	T-Cells	Preclinical Discovery	Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity	Science Advances, 2023	IsoCode Single-Cell Adaptive Immune: Human PBMC
Immunosuppression	T-Cells	Preclinical Discovery	Distinct immune signature predicts progression of vestibular schwannoma and unveils a possible viral etiology	Journal of Experimental & Clinical Cancer Research, 2022	IsoCode Single-Cell Adaptive Immune: Human PBMC
Proliferation	NK Cells	Preclinical Discovery	CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk	Nature Genetics, 2022	Single-Cell Intracellular Proteome: HeLa Cell
Resistance	Melanoma	Preclinical Discovery	Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line	Nature Communications, 2020	Tumor Cell
Resistance	Melanoma	Preclinical Discovery	Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance	PNAS, 2017	Tumor Cell
Resistance	Glioblastoma	Preclinical Discovery	Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma	Cancer Cell, 2016	Tumor Cell

Our Unique Biology

Proteomics, Reimagined to uniquely detect our most powerful cells.

IsoLight Virtual Demo

The entire ELISA proteomics workflow, sample to answer.

Data Visualizations

IsoSpeak Software: Same day visualizations and insights.